Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

A novel compound called Lorcaserin helped overweight and obese people lose about 5 percent of their body weight, according to a study published today in the New England Journal of Medicine. While the weight reduction is modest, the drug could have fewer side effects than others that appear to be more effective.

The drug, developed by San Diego-based Arena Pharmaceuticals, acts on a specific subset of receptors for the chemical messenger serotonin. These receptors play a role in satiety, the feeling of fullness.

The company has been working to develop such a compound since the 1990s, when research linked appetite to some serotonin receptors in the brain. “This is the first tailor-made molecule to target receptors involved in producing satiety and reducing caloric intake,” says Arne Astrup, a physician at the University of Copenhagen, who wrote an editorial accompanying the paper in the NEJM. “I think we now have a much better understanding of the biology of these systems working in the brain and the peripheral effects than we did when some of the first compounds came on market. I think we feel more confident that this is a safe drug.”

Several weight-loss drugs have been pulled from the market or abandoned in late-stage development because of dangerous side effects. Long-term safety is a major concern, since previous studies suggest that in many cases such drugs must be taken continuously to maintain weight loss. “Weight-loss drugs only work as long as you take them,” says Steven Smith, a physician at Florida Hospital in Winter Park, FL, who led the study and is a paid consultant to Arena. “They are more like cholesterol or blood-pressure drugs than antibiotics, which cure an infection and can then be stopped.”

Lorcaserin was designed to target a subset of serotonin receptors called 5-HTC2. This specificity is in contrast to that of fenfluramine, a weight-loss drug often prescribed in the 1990s in combination with a second drug called phentermine (the combination was known as fen-phen). Fenfluramine was pulled off the market in 1997 after it was linked to heart-valve problems and pulmonary hypertension. These side effects were thought to come from the drug’s action on a set of serotonin receptors, 5-HT2B, found on heart and lung cells. By targeting brain receptors specifically, Lorcaserin appears to avoid these side effects.

In the new study, funded by Arena, scientists studied more than 3,000 people; half were given the drug, half took a placebo. After a year, approximately 55 percent of the drug group and 44 percent of the placebo group remained in the trial. Nearly 50 percent of the Lorcaserin group lost 5 percent of their body weight, compared to about 20 percent of the placebo group. About 20 percent of the drug group lost 10 percent of their body weight, compared to 7 percent of the placebo group. (Weight loss of about 10 percent is linked to decreases in cholesterol level and blood sugar.) Those who took the drug for a second year were more likely to maintain their weight loss; nearly 70 percent did so, compared to about half of those given a placebo in the second year.

4 comments. Share your thoughts »

Credit: Courtesy of Tony Alter

Tagged: Biomedicine, obesity, weight loss

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me
×

A Place of Inspiration

Understand the technologies that are changing business and driving the new global economy.

September 23-25, 2014
Register »